

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITHOUT DTT OF SAMPLE 2A08/2017 WB

DESPATCHED ON 18TH JULY 2017

HLA PHENOTYPE OF BLOOD DONOR: A2, A29; B8, B44; Cw7, Cw16; DR11, DR17; DQ2, DQ7

					Summary of Results													
					PBL				T-Cells				B-Cells					
					7	8	8	8	19	19	19	19	16	14	15	15		
					2	0	0	0	0	0	0	0	14	3	5	1		
					5	8	8	8	19	19	19	19	2	11	10	14		
					3	2	2	2	1	1	1	1	5	7	6	6		
					28.6%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	87.5%	21.4%	33.3%	6.7%		
					71.4%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	12.5%	78.6%	66.7%	93.3%		
Consensus					Not Assessed	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	Not Assessed	Negative		
HLA Antibody Specificity (Defined By CDC)					DR3	A32 B44 DR7	DR5 DR6 DQ6	B7 DR2	DR3	A32 B44 DR7	DR5 DR6 DQ6	B7 DR2	DR3	A32 B44 DR7	DR5 DR6 DQ6	B7 DR2		
					Without DTT				Without DTT				Without DTT					
Lab No.	PBL Assessment	T Cell Assessment	B Cell Assessment		Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	Comments	
9	YES	YES	YES		Positive	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	Positive	Negative	PBL not tested due to low cell numbers Poor B-cell viability No B cell crossmatching performed due to issues with Dynabead supply B cell condition poor, high backgrounds with all samples High background with B cells. Samples reported as equivocal where the result was ambiguous relative to the increased background. B-cell results not reported due to Dynabead recall	
11	YES	YES	YES		NT	NT	NT	NT	Negative	Negative	Negative	Negative	Positive	Positive	Positive	Positive		
12	YES	YES	YES		Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	NT	Negative	NT		
20	YES		YES		Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	NT	NT	NT	NT		
23		YES	YES						Negative	Negative	Negative	Negative	Positive	Negative	Negative	Negative		
24		YES	YES						Negative	Negative	Negative	Negative	Positive	Equivocal	Equivocal	Negative		
25		YES	YES						Negative	Negative	Negative	Negative	NT	NT	NT	NT		
28		YES	YES						Negative	Negative	Negative	Negative	Positive	Negative	Negative	Negative		
34		YES	YES						Negative	Negative	Negative	Negative	Positive	Negative	Negative	Negative		
35	YES	YES			Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative						
38	YES	YES	YES		Positive	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Positive	Positive	Negative		
39		YES	YES						Negative	Negative	Negative	Negative	Positive	Negative	Negative	Negative		
41		YES	YES						Negative	Negative	Negative	Negative	Positive	Negative	Negative	Negative		
42	YES		YES		Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Positive	Positive	Negative		
45		YES	YES						Negative	Negative	Negative	Negative	Positive	Negative	Negative	Negative		
51		YES	YES						Negative	Negative	Negative	Negative	Positive	Negative	Negative	Negative		
54		YES	YES						Negative	Negative	Negative	Negative	Positive	Negative	Positive	Negative		
58		YES	YES						Negative	Negative	Negative	Negative	NT	NT	NT	NT		
117	YES				Equivocal	Negative	Negative	Negative										Poor viability. In a clinical setting we would repeat the test
136									Negative	Negative	Negative	Negative						
149	YES		YES		Negative	Negative	Negative	Negative					NT	NT	NT	NT	Poor cell viability	
205	YES		YES		NT	NT	NT	NT					Negative	Negative	Negative	Negative		
212		YES	YES						Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative		
311		YES	YES						Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative		
315		YES	YES						NT	NT	NT	NT	Negative	Negative	Negative	Negative	Samples received on the 20th of July, displaying a strong basal cellular mortality. Uninterpretable tests.	

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITHOUT DTT OF SAMPLE 2A08/2017 WB

DESPATCHED ON 18TH JULY 2017

Lab No.	PBL without DTT				T-cell without DTT				B-cell without DTT				Cell viability %		
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	PBL	T-cells	B-cells
9	4	-	-	-	-	-	-	-	6	-	2	-	95	95	95
11	NT	NT	NT	NT	1	1	1	1	8	6	6	4		90	70
12	1	1	1	1	1	1	1	1	6	NT	4	NT	98	98	75
20	0	0	0	0					NT	NT	NT	NT	100		
23					1	1	1	1	8	1	1	1		95	60
24					20	10	20	20	100	50	50	40		90	60
25					1	1	1	1	NT	NT	NT	NT		95	
28					1	1	1	1	8	2	1	1		99	90
34					1	1	1	1	4	1	1	1		99	
35	2	2	2	2	2	2	2	2					90	90	
38	2	1	1	1	1	1	1	1	8	6	4	1	90	90	90
39					-	-	-	-	8	-	-	-		90	90
41					10	4	6	2	91	0	0	0		90	90
42	<10	<10	<10	<10					>80	20-40	20-40	<10	95		
45					1	1	1	1	4	1	1	1		99	85
51					0	0	0	0	8	0	0	0		95	95
54					5	5	5	5	95	10	80	5		95	90
58					5	5	5	5	NT	NT	NT	NT		95	30
117	Equivocal	1	1	1									65		
136					1	1	1	1						96	
149															
205	NT	NT	NT	NT					NT	NT	NT	NT			
212					-	-	-	-	-	-	-	-		100	100
311					1	1	1	1	1	1	1	1		90	90
315					NT	NT	NT	NT	NT	NT	NT	NT		<10	<10

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITH DTT OF SAMPLE 2A08/2017 WB

DESPATCHED ON 18TH JULY 2017

HLA PHENOTYPE OF BLOOD DONOR: A2, A29; B8, B44; Cw7, Cw16; DR11, DR17; DQ2, DQ7

				Summary of Results												
				PBL				T-Cells				B-Cells				
Total tested	7	7	7	7	17	17	17	17	15	13	15	14				
Positive	2	0	0	0	0	0	0	0	13	3	5	1				
Negative	5	7	7	7	17	17	17	17	2	10	10	13				
NT/Equivocal	2	2	2	2	1	1	1	1	5	7	5	6				
% Positive	28.6%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	86.7%	23.1%	33.3%	7.1%				
% Negative	71.4%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	13.3%	76.9%	66.7%	92.9%				
Consensus	Not Assessed	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	Not Assessed	Negative				
HLA Antibody Specificity (Defined By CDC)	DR3	A32 B44 DR7	DR5 DR6 DQ6	B7 DR2	DR3	A32 B44 DR7	DR5 DR6 DQ6	B7 DR2	DR3	A32 B44 DR7	DR5 DR6 DQ6	B7 DR2				
Lab No.	PBL Assessment	T Cell Assessment	B Cell Assessment	With DTT				With DTT				With DTT				Comments
				Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	
9	YES	YES	YES	Positive	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Negative	Positive	Negative	PBL not tested due to low cell numbers
11	YES	YES	YES	NT	NT	NT	NT	Negative	Negative	Negative	Negative	Positive	Positive	Positive	Positive	Poor B-cell viability
12	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	NT	Negative	NT	
15		YES	YES					Negative	Negative	Negative	Negative	Positive	Negative	Positive	Negative	
20	YES		YES	Negative	Negative	Negative	Negative					NT	NT	NT	NT	No B cell crossmatching performed due to issues with Dynabead supply
24		YES	YES					Negative	Negative	Negative	Negative	Positive	Equivocal	Negative	Negative	High background with B cells. Samples reported as equivocal where the result was ambiguous relative to the increased background.
25		YES	YES					Negative	Negative	Negative	Negative	NT	NT	NT	NT	B-cell results not reported due to Dynabead recall
28		YES	YES					Negative	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
34		YES	YES					Negative	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
35	YES	YES		Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative					
38	YES	YES	YES	Positive	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Positive	Positive	Positive	Negative	
39		YES	YES					Negative	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
41		YES	YES					Negative	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
42	YES		YES	Negative	Negative	Negative	Negative					Positive	Positive	Positive	Negative	
45		YES	YES					Negative	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
51		YES	YES					Negative	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
58		YES	YES					Negative	Negative	Negative	Negative	NT	NT	NT	NT	
149	YES			Negative	Negative	Negative	Negative					NT	NT	NT	NT	Poor cell viability
205	YES		YES	NT	NT	NT	NT					Negative	Negative	Negative	Negative	
212		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
311		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
315		YES	YES					NT	NT	NT	NT	Negative	Negative	Negative	Negative	Samples received on the 20th of July, displaying a strong basal cellular mortality. Uninterpretable tests.

UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITH DTT OF SAMPLE 2A08/2017 WB

DESPATCHED ON 18TH JULY 2017

Lab No.	PBL with DTT				T-cell with DTT				B-cell with DTT				Cell viability %		
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	PBL	T-cells	B-cells
9	4	-	-	-	-	-	-	-	6	-	2	-	95	95	95
11	NT	NT	NT	NT	1	1	1	1	8	6	6	6		90	70
12	1	1	1	1	1	1	1	1	8	NT	4	NT	98	98	75
15					0	0	0	0	8	0	2	0		70	70
20	0	0	0	0					NT	NT	NT	NT	100		
24					20	20	20	20	100	50	40	40		90	60
25					1	1	1	1	NT	NT	NT	NT		95	
28					1	1	1	1	8	1	1	1		99	90
34					1	1	1	1	4	1	1	1		99	
35	2	2	2	2	2	2	2	2					90	90	
38	2	1	1	1	1	1	1	1	8	6	4	1	90	90	90
39					-	-	-	-	8	-	-	-		90	90
41					5	3	0	0	90	0	4	0		90	90
42	<10	<10	<10	<10					>80	20-40	60-80	<10	95		
45					1	1	1	1	4	1	1	1		99	85
51					0	0	0	0	NT	NT	NT	NT		95	95
58					5	5	5	5	NT	NT	NT	NT		95	30
149													82		
205	NT	NT	NT	NT					NT	NT	NT	NT			
212					-	-	-	-	-	-	-	-		100	100
311					1	1	1	1	1	1	1	1		90	90
315					NT	NT	NT	NT	NT	NT	NT	NT		<10	<10